This year saw the regulatory approval of the first dual GIP/GLP-1 dual agonist for type 2 diabetes. With several other multi-agonists in development, what does this mean for clinicians caring for people with type 2 diabetes?
Join Prof. Filip Knop for an overview of these new and emerging agents.
By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.
Disclosures:
Prof. Filip Knop declares the following financial relationships from the past 24 months:
Honorarium recipient: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi
Speakers Bureau: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi
Consultant (Occasional): AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi
Advisor or Review Panel member: Eli Lilly, Novo Nordisk, Sanofi
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Funding:
This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.